Ketamine One Capital limited (OTCMKTS:KONEF) Stock Consolidates After Recent News
Ketamine One Capital limited (OTCMKTS:KONEF) is moving in a range after the company targeting medical consolidation and being a leader in mental health therapies announced the lifting of its British Columbia Securities Commissions management cease trade order given on November 1, 2021.
Market Stats
On Wednesday, KONEF stock ended flat at $0.3368 with more than 200 shares, compared to its average volume of 700 shares. The stock has moved within a range of $0.3368 – 0.3368 after opening trading at $0.3368.
Ketamine One Announces Lifting of Management Cease Trade Order
The order’s lifting is effective immediately after the SEDAR filing on December 13, 2021, of Ketamine One’s annual audited financial results and management’s analysis and discussion for the fiscal year ending July 31, 2021.
KetaminOne was formerly called Myconic Capital Corp and has been working to offer the vital infrastructure required to create and deliver novel mental health therapies. Currently, the company has a network of clinics in North America, and it plans to consolidate this highly fragmented sector. In addition, its wholly-owned contract research unit KGK Science Inc. is at the forefront of high-quality clinical research based on extensive experience and history in cannabis, pharmaceuticals, and upcoming psychedelic medicine sectors. Therefore, KONEF is a stock investors should watch in the coming weeks.
Traders Corner
KONEF stock is trading above the 20-Day and 50-Day Moving averages of $0.32 and $0.31 respectively. However, the stock is trading below the 200-Day moving average of $0.86. The stock is down 8% in the past month.
